Ascendis Pharma A/S (ASND) Reports 5-Year Kidney Function Gains With TransCon PTH

What happened

Ascendis Pharma A/S reported pooled Phase 2/3 data showing early and sustained kidney function (eGFR) improvements and lower urine calcium in adults with hypoparathyroidism treated with TransCon PTH for up to 5 years.

Confirmed

Global impact / market context

Longer-term kidney data may support TransCon PTH, sold as YORVIPATH in the US and EU, as a durable treatment. Better kidney and calcium outcomes could help adoption and payer reimbursement, which supports product revenue growth.

Analyst inference

The findings extend earlier efficacy and safety signals after approval, which may strengthen the product's competitive position. Still, this is a post-hoc analysis, so investors may treat the results as supportive but not definitive until peer-reviewed data arrive.

Analyst inference

What to watch

1. Ascendis said 129 patients completed the trials, which suggests tolerability but leaves a moderately sized sample for long-term chronic data. Confirmed
2. Watch for peer-reviewed publication and harder kidney function and event-rate data, which would turn the post-hoc findings into firmer evidence for long-term kidney benefit. Proposed
3. Track real-world use and payer decisions for YORVIPATH, because adoption and reimbursement are the main routes by which durable data reach company revenue. Analyst inference

Evidence

• globenewswire.com